Skip to main content

Publications, Studies, Posters and Abstracts

Society for Neuro-Oncology 2022The HER2 Flip: HER2 Amplification of Tumor Cells in the Cerebrospinal Fluid (CSF-TCs) of Patients with Leptomeningeal Metastasis Having Solid Tumors; Implications for Treating the LM Tumor with Anti_HER2 TherapyBreast Cancer, CNS Metastases2022breast-cancer cns-metastases2022

Society for Neuro-Oncology 2022

The Detection of Disseminated Pineal Parenchymal Tumor of Intermediate Differentiation (PPTID) in Cerebrospinal Fluid (CSF) Using Cell Capture and ImmunocytochemistryCNS Metastases2022cns-metastases2022

Society for Neuro-Oncology 2022

Detection of Mutant p53 Positive Glioblastoma Cells in Cerebrospinal Fluid (CSF) Using a Microfluidic Based ImmunoassayCNS Metastases2022cns-metastases2022

Clinical Breast Cancer 2022

Diagnosis of Leptomeningeal Metastasis in Women With Breast Cancer Through Identification of Tumor Cells in Cerebrospinal Fluid Using the CNSide™ AssayCNS Metastases2022cns-metastases2022

American Academy of Neurology 2022

Using Cerebrospinal Fluid Tumor Cell (CSF-TC) Assays to Track Disease Burden and Treatment Response in Patients with Leptomeningeal MetastasisCNS Metastases2022cns-metastases2022

San Antonio Breast Cancer Symposium 2021

Characterization of HER2 Amplification in the Cerebrospinal Fluid of Patients with Leptomeningeal Disease in Stage IV Patients with Breast CancerBreast Cancer, CNS Metastases2021breast-cancer cns-metastases2021

Society for Neuro-Oncology 2021

Case Series of Multi-Institutional Utility of CNSide™ to Manage Leptomeningeal Disease in Patients with Metastatic Breast CancerBreast Cancer, CNS Metastases2021breast-cancer cns-metastases2021

SNO Brain Metastases 2021

Beyond Cytology – A Single Institution Experience Using CNSide™ for Diagnosing and Monitoring Treatment Response in Non-Small Cell Lung Cancer with Leptomeningeal Carcinomatosis (LMC)CNS Metastases2021cns-metastases2021

Molecular Med Tri-Con 2021

Detection of EGFR Mutations in Quantity Insufficient Tissue Slides by High Sensitivity Assay Target Selector™ in Patients with Non-Small Cell Lung CancerLung Cancer2021lung-cancer2021

ASCO 2020

Diagnosis of leptomeningeal metastasis (LM) through identification of circulating tumor cells (CTCs) in cerebrospinal fluid (CSF)Technology Platform2020technology-platform2020

International Association for the Study of Lung Cancer (IASLC) 2020

Utility of Liquid Biopsy in Diagnosis and Treatment Response in EGFR Mutant NSCLC Patients with Leptomeningeal InvolvementLung Cancer2020lung-cancer2020

Society for Neuro-Oncology 2020

Target Selector™ cerebrospinal fluid (CSF) circulating tumor cells and biomarker analysis: improving sensitivity and targeted treatment options in breast and NSCLC cancer patients with CNS involvementLung Cancer2020lung-cancer2020

San Antonio Breast Cancer Virtual Symposium 2020

HER2 Expression in Matched Metastatic Tumor and Circulating Tumor Cells (CTCs) In Breast Cancer: Implications for profiling and monitoring of HER2 statusBreast Cancer2020breast-cancer2020

University of Missouri at Kansas City, Kansas City 2019

Clinical utility of circulating tumor cell (CTC) analysis in patients with metastatic NSCLC receiving first-line chemotherapyLung Cancer2019lung-cancer2019

UC San Diego Health System 2019

Surrogate or Not: The Role for Cell Free Circulating DNA in Detecting EGFR Mutations Present in Tumor TissueBiomarkers2019biomarkers2019


Analytical validation of the Target Selector ctDNA platform featuring single copy detection sensitivity for clinically actionable EGFR, BRAF, and KRAS mutationsLung Cancer2019lung-cancer2019

Clinics in Oncology – Breast Cancer 2019

Clinical Utility of Target Selector™ Circulating Tumor Cell (CTC) Testing in Tumor Marker Gene Amplification and Protein Expression in Metastatic Breast Cancer ManagementBreast Cancer2019breast-cancer2019

Clinics in Oncology – General Oncology 2019

Demonstrated Clinical Utility of Target Selector™ ctDNA Testing: Liquid Biopsy EGFR Mutation Detection Enabled Targeted Therapy Selection for Three Advanced NSCLCLung Cancer2019lung-cancer2019

AMP 2019

Highly sensitive and specific detection of Cytokeratin Positive and Negative Circulating Tumor CellsTechnology Platform2019technology-platform2019

AMP 2019

Target Selector™ DNA EGFR kit for tissue demonstrates high sensitivity without the need for macro-dissectionBiomarkers2019biomarkers2019

AMP 2019

Mutant-p53 antibody stains cytokeratin negative CTCs enriched and detected with a “Pan-CTC” antibody cocktailBiomarkers2019biomarkers2019

AMP 2019

Detection of Potential Epithelial Mesenchymal Transition Cells in Localized Prostate CancerProstate Cancer2019prostate-cancer2019

AMP 2019

Monitoring breast cancer biomarkers from circulating tumor DNA using Target Selector™ NGS Breast PanelBreast Cancer2019breast-cancer2019

AMP 2019

Validation of Target Selector™ Next Generation Sequencing Lung Panelfor the Detection of Circulating Tumor TNA AlterationsLung Cancer2019lung-cancer2019

AACR 2019

Validation of a highly sensitive Target Selector™ ctDNA assay for ESR1 resistance mutations using an NGS enrichment strategyBiomarkers2019biomarkers2019

World Conference in Lung Cancer 2019

The Dynamic Range of Mutant Allele Fraction Detected in Patients with NSCLC: Clinical Experience Data and Clinical ImplicationsLung Cancer2019lung-cancer2019

San Antonio Breast Cancer Symposium 2019

Clinical Data in Over 1,500 Patients Across All Stages of Breast Cancer with Target Selector™ Circulating Tumor Cell TechnologyBreast Cancer2019breast-cancer2019

Oncology & Hematology Review 2018

Detecting an ALK Rearrangement via Liquid Biopsy Enabled a Targeted Therapy-based Approach for Treating a Patient with Advanced Non-small Cell Lung CancerLung Cancer2018lung-cancer2018

Journal of Thoracic Oncology 2018

ROS-1 Rearrangements in Circulating Tumor CellsBiomarkers2018biomarkers2018

Biomarkers Summit 2018

Microfluidic Assay Detects dMMR in Circulating Tumor Cells (CTCs)Biomarkers2018biomarkers2018


Validation of the QuantStudio5 Instrument for Use in Biocept’s TargetSelector™ ctDNA Lung Cancer AssaysTechnology Platform2018technology-platform2018

AACR 2018

TargetSelector™ CTC technology demonstrates clinical utility in monitoring treatment response in germ cell tumors (testicular cancer)Technology Platform2018technology-platform2018

AACR 2018

Validation of Highly Sensitive Target Selector™ ctDNA Assays for EGFR, BRAF, and KRAS MutationsBiomarkers2018biomarkers2018

World Conference in Lung Cancer 2018

Analysis and Monitoring CTCs and ctDNA in CSF Demonstrates Clinical Concordance in Tesevatinib Treated NSCLC Patients with LMLung Cancer2018lung-cancer2018

Journal of Thoracic Oncology 2017

Clinical Utility of Plasma EGFR T790M Mutation Detection in Advanced Non-Small Cell Lung Cancer Patients According to RECIST CriteriaLung Cancer2017lung-cancer2017

ASCO 2017

Biocept’s Sample Collection for Tumor Cell Analysis Demonstrates Superior PerformanceTechnology Platform2017technology-platform2017

ASCO 2017

Clinical Experience in ctDNA Profiling of NSCLC 2000 Cases Using TargetSelector™ Demonstrates High SensitivityLung Cancer2017lung-cancer2017

AACR 2017

A concordance study of the ArcherDx Reveal ctDNA 28 NGS panel and Biocept’s Target-Selector™ mutation assay using ctDNA collected in Biocept’s CEE-sure blood collection tubeTechnology Platform2017technology-platform2017

ESMO 2016

Clinical evaluation of the utility of a liquid biopsy (Circulating tumoral cells and ctDNA) to determine the mutational profile (EGFR, KRAS, ALK, ROS1 and BRAF) in advanced NSCLC patients.Lung Cancer2016lung-cancer2016

ASCO 2016

The performance of a comprehensive CTC anti-body capture cocktail in the detection and phenotypic analysis of CTCsTechnology Platform2016technology-platform2016

San Antonio Breast Cancer Symposium 2016

Circulating Tumor Cell (CTC) Biomarker Evaluation from Patients with Metastatic Breast Cancer (MBC) Utilizing the Target Selector™ PlatformBreast Cancer2016breast-cancer2016

Clinical Translational Oncology 2015

Correlation of hormone receptor status between circulating tumor cells, primary tumor and metastasis in breast cancer patientsBreast Cancer2015breast-cancer2015

ASCO 2015

Clinical validation and utility of a liquid biopsy for non-small cell lung carcinoma utilizing CTCs and ctDNA to analyze ALK, ROS and EGFR statusLung Cancer2015lung-cancer2015

AACR 2015

High Sensitivity Detection of Rare EGFR Mutations with ctDNA using Target-Selector™ AssaysBiomarkers2015biomarkers2015

Molecular Assay Development 2015

Validation of PD-L1 Expression on Circulating Tumor Cells in Lung CancerLung Cancer2015lung-cancer2015

San Antonio Breast Cancer Symposium 2014

Prospective characterization of HER2-positive circulating tumor cells in patients with HER2- negative metastatic breast cancerBreast Cancer2014breast-cancer2014

Cancer Cell 2014

Hematogenous Metastasis of Ovarian Cancer: Rethinking Mode of SpreadOvarian Cancer2014ovarian-cancer2014

Cancer Medicine 2013

Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancerBiomarkers2013biomarkers2013

ASCO 2012

Estrogen receptor and progesterone receptor immunocytochemistry staining in circulating tumor cells as compared to primary tumor or metastatic biopsyBiomarkers2012biomarkers2012

ASCO 2012

Detection of discordant HER2 status by FISH in circulating tumor cells and disseminated tumor cells in early stage breast cancer using a microfluidicbased cell enrichment and extraction platform (OncoCEE™)Biomarkers2012biomarkers2012

ASCO 2012

Mutational analysis of circulating tumor cells in breast cancer patients by targeted clonal sequencingBreast Cancer2012breast-cancer2012

AACR 2012

The CEE-Selector™ Assay: A tool for the identification of rare allele variantsTechnology Platform2012technology-platform2012

San Antonio Breast Cancer Symposium 2011

Estrogen receptor and progesterone receptor immunocytochemistry staining in circulating tumor cells as compared to primary tumor or metastatic biopsyBiomarkers2011biomarkers2011

San Antonio Breast Cancer Symposium 2011

Detection of HER2 gene amplification in circulating tumor cells and disseminated tumor cells by fluorescence in situ hybridization using OncoCEE™Biomarkers2011biomarkers2011

Molecular Med Tri-Con 2011

Detection of EpCAM-negative and Cytokeratin-negative Circulating Tumor Cells in Peripheral BloodTechnology Platform2011technology-platform2011

Cancer Genetics 2011

FISH-based determination of HER2 status in circulating tumor cells isolated with the microfluidic CEE™ platformBiomarkers2011biomarkers2011

Cancer Discovery 2011

A Novel Platform for Detection of CK+ and CK- CTCsTechnology Platform2011technology-platform2011

Biomicrofluidics 2011

Efficient capture of circulating tumor cells with a novel immunocytochemical microfluidic deviceTechnology Platform2011technology-platform2011

Biomicrofluidics 2011

Efficient Capture of Suspended Tumor Cells with a Novel Immunocytochemical Microfluidic DeviceTechnology Platform2011technology-platform2011

ASCO 2011

Redefining CTCs: Detection of additional circulating tumor cells using an antibody capture cocktail and HER2 FISHTechnology Platform2011technology-platform2011

ASCO 2011

Detection of HER2 status of circulating tumor cells and disseminated tumor cells using a microfluidic platform (cell enrichment and extraction technology [CEE™])Biomarkers2011biomarkers2011

AACR 2011

Fluorescence labeling of cytokeratin-negative circulating tumor cells in peripheral blood: A new paradigm for the study of cancer progressionTechnology Platform2011technology-platform2011

AACR 2011

Redefining CTCs: Detection of cytokeratin-negative circulating tumor cells (CTCs)Technology Platform2011technology-platform2011

The Journal of Urology 2010

Recovery of Circulating Tumor Cells in Urothelial Carcinoma Cell Lines Utilizing a Novel Antibody Based Microfluidic Cell Capture TechniqueTechnology Platform2010technology-platform2010

San Antonio Breast Cancer Symposium 2010

Detection of circulating tumor cells and HER2 gene amplification status in breast cancer using a novel microfluidic platform (Cell Enrichment and Extraction Technology, CEE™)Biomarkers2010biomarkers2010
CEE™ Cell Enrichment and Extraction Technology Enabling Early, Non-invasive Isolationof Rare Cells for DiagnosticsTechnology Platform2007technology-platform2007
Mouse Models for MEMS (Micro-Electro-Mechanical System) Based Biomarker Discovery: A Novel CTC Mouse-TrapTechnology Platformtechnology-platform
Comparison of fluorescence in situ hybridization of estrogen receptor genetic locus with protein expression in invasive breast carcinomaTechnology Platformtechnology-platform